Previous Close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expire Date | 2024-10-18 |
Day's Range | 0.1500 - 0.1500 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
FREMONT, Calif., May 22, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois.
FREMONT, Calif., May 17, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan.
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript May 8, 2024 Personalis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Personalis First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event […]